$3 Billion Settlement reached in Whistleblower lawsuit with GlaxoSmithKline

Settlement Amount: 

A settlement has been reached in a whistleblower class action lawsuit brought against GlaxoSmithKline who is accused of promoting some of its antidepressants for unapproved uses and failing to report safety data about a top diabetes drug and improper marketing of a half-dozen other drugs.

The settlement includes $1 billion in criminal fines and $2 billion in civil fines.  $300 million of the settlement will go to states and other public health authorities.  A portion of the civil fine will go to the contributing whistleblowers.

The case was originally filed in 2012 in the U.S. District Court for the District of Massachusetts.

If you have a similar case please fill out the form below or email mail@whistleblowerinstitute.com or call: 619-452–1218


If you or someone you know experienced a similar situation or any other wrongdoing within a corporation you should contact mail@whistleblowerinstitute.com or call: 619-452–1218

Go to top